Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles

Sapna Kashyap; Amit Singh; Abha Mishra; Vikas Singh

doi:10.4103/1735-5362.253356

Enhanced sustained release of furosemide in long circulating chitosan-conjugated PLGA nanoparticles

Res Pharm Sci. 2019 Mar 8;14(2):93-106. doi: 10.4103/1735-5362.253356. eCollection 2019 Apr.

Authors

Sapna Kashyap¹, Amit Singh¹, Abha Mishra², Vikas Singh³

Affiliations

¹ Department of Pharmacology, Institute of Medical Sciences, Banaras Hindu University, Varanasi -221005, India.
² School of Biochemical Engineering, Indian Institute of Technology, Banaras Hindu University, Varanasi -221005, India.
³ Department of Chemical Engineering, Indian Institute of Technology-Delhi, New Delhi- 110016, India.

Abstract

Furosemide (FSM) is commonly used in the treatment of edema associated with congestive cardiac failure, cirrhosis of the liver, renal disease, including the nephrotic syndrome and hypertension. However, in ascites, it is clinically limited due to its frequent dosing and short biological half-life and its prolonged-release preparations are not available. Therefore, the main objective behind the present research work is to develop chitosan coated and conjugated poly (lactic-co-glycolic acid) (PLGA) nanocarriers, to sustain the delivery of FSM with improved systemic circulation. Emulsion-solvent evaporation technique was used for the preparation of nanoparticles. In-vivo pharmacokinetic study showed 2.6, 3.10, and 4.30 folds enhancement in relative availability of FSM for FSM-PLGA, FSM-chitosan-coated-PLGA and FSM-chitosan-conjugated- PLGA nanoparticles, respectively than FSM. The present research work concluded that FSM loaded chitosan conjugated PLGA nanoparticles could enhance the systemic circulation of FSM with improved pharmacokinetics parameters.

Keywords: Chitosan; FSM; Nanocarriers; PLGA; Polymeric nanoparticles; Sustained effect.